Security key
10501E300
BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI)
CUSIP: 10501E300
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.00005 par value
- Total 13F shares
- 235,778
- Total 13F value
- $263,958
- Share change
- -630,246
- SEC-reported price per share
- $1.12
- Number of holders
- 33
- Value change
- -$804,996
- Number of buys
- 11
- Number of sells
- 8
- Shares outstanding
- 6,002,966
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
33
Top holders
10
BCLI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
BRAINSTORM CELL THERAPEUTICS INC. SEC filings
BRAINSTORM CELL THERAPEUTICS INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 10501E300
Recent filing periods:
Ownership snapshot
Top reported holders of BCLI - BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Sankesh Abbhi
Comparable rows
1/15
Latest evidence
31 Mar 2025
13F
13D/G
3/4/5
Lead comparable stake: 10%
14 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 1
ARMISTICE CAPITAL, LLC
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
10%
Reported 13D/G
· 31 Mar 2025
|
$870,239
690,666 shares
|
— | 31 Mar 2025 |
| Sankesh Abbhi |
3/4/5
Director
|
—
denominator unverified
|
$3,860,181
2,175,853 shares
|
— | 10 Dec 2021 |
| Ralph Dr. Kern |
3/4/5
COO and Chief Medical Officer
|
—
denominator unverified
|
$396,174
223,310 shares
|
— | 06 Mar 2022 |
| Malcolm S. Taub |
3/4/5
Director
|
—
denominator unverified
|
$137,195
77,332 shares
|
— | 15 Dec 2021 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$73,303
58,165 shares
|
— | 31 Mar 2025 |
| Kirk Taylor |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$62,094
115,000 shares
mixed-class rows
|
— | 01 May 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
33
Shares
235,778
Rows available
33
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q3 2025 Across Filers
Q3 2025 holders
5
Q2 2025 holders
33
Holder diff
28
| Investor | Q3 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend